Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital

October 30, 2021 updated by: Ekram Farouk Ibrahim, Assiut University
study epidemiology of lupus nephritis patients admitted to nephrology unit inward or in outpatient clinic in Assiut Nephrology Unit

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

this study are:

To describe socio-demographic characteristics of lupus nephritis patients in Nephrology Unit of Assiut University hospital ( Old and New cases).

To determine the associated risk factors in the study population

To describe the clinical, laboratory characteristics, treatment modalities of lupus nephritis patients in Nephrology Unit of Assiut University hospital ( Old and New cases)

To Identify outcomes of treatment of these cases within 2 years according to different classes

To evaluate the effectiveness of (type of interventions mentioned) among those patients.

Study Type

Observational

Enrollment (Anticipated)

60

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All patients admitted to nephrology unit or visiting the outpatient nephrology clinic, previously or newly diagnosed with lupus nephritis in Internal Medicine Department in assiut University hospital will be recruited from December 2021 till May 2022.

Description

Inclusion Criteria:

  • all patients admitted to nephrology unit or visiting the outpatient nephrology clinic,previously or newly diagnosed with lupus nephritis.

Exclusion Criteria:

  • incomplete Criteria for diagnosis of systemic lupus or presence of associated renal disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Study of epidemiology of lupus nephritis patients
Time Frame: 6 months
Detection of different risk factors such as socioeconomic status and its relation to lupus nephritis To study the outcome of treatment plans in different classes of lupus nephritis
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2021

Primary Completion (Anticipated)

May 1, 2022

Study Completion (Anticipated)

June 1, 2022

Study Registration Dates

First Submitted

October 30, 2021

First Submitted That Met QC Criteria

October 30, 2021

First Posted (Actual)

November 15, 2021

Study Record Updates

Last Update Posted (Actual)

November 15, 2021

Last Update Submitted That Met QC Criteria

October 30, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • lupus nephritis

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe